Jayud Global Logistics Issues Statement Regarding Market Activity
While it is the Company's practice not to comment on any stock movement, we must caution investors and all other persons to rely solely on statements and filings with the United States Securities and Exchange Commission issued by the Company itself or its authorized representatives. The Company does not intend to make further statements regarding this matter.
About Jayud Global Logistics Limited
Jayud Global Logistics Limited is one of the leading Shenzhen-based end-to-end supply chain solution providers in China, focusing on cross-border logistics services. Headquartered in Shenzhen, the Company benefits from the unique geographical advantages of providing a high degree of support for ocean, air, and overland logistics. The Company has established a global operation nexus featuring logistic facilities throughout major transportation hubs in China and globally, with footprints in 12 provinces in Mainland China and 16 countries across six continents. Jayud offers a comprehensive range of cross-border supply chain solution services, including freight forwarding, supply chain management, and other value-added services. With its strong service capabilities and research and development capabilities in proprietary IT systems, the Company provides customized and efficient logistics solutions and develops long-standing customer relationships. For more information, please visit the Company's website: https://ir.jayud.com.
Forward-Looking StatementsCertain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs, including the expectation that the Offering will be successfully completed. Investors can identify these forward-looking statements by words or phrases such as 'may', 'will', 'expect', 'anticipate', 'aim', 'estimate', 'intend', 'plan', 'believe', 'is/are likely to', 'potential', 'continue' or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC.
For more information, please contact:
Jayud Global Logistics LimitedInvestor Relations DepartmentEmail: ir@jayud.com
Investor Relations Contact:Matthew Abenante, IRCPresidentStrategic Investor Relations, LLC Tel: 347-947-2093Email: matthew@strategic-ir.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
15 minutes ago
- Indianapolis Star
There's just a month until TikTok could be banned – again. Here's where things stand.
President Donald Trump has one month to finalize the sale of TikTok or the short-form video platform risks going dark in the U.S. – again. For months, Trump has said negotiations for the sale of TikTok have been ongoing with China, as the platform is owned by Beijing-based ByteDance. Since the platform went dark for less than 24 hours in January, Trump has extended the deadline on a ban of TikTok in the U.S. three times. And he may just conduct a fourth. In late July, U.S. Commerce Secretary Howard Lutnick said in a CNBC interview that if China did not approve a U.S.-drafted deal to sell the platform's American assets, the app would go dark again, once the next ban extension expires on Sept. 17. "If that deal gets approved by the Chinese, then that deal will happen. If they don't approve it, then TikTok is going to go dark," Lutnick previously said. "And those decisions are coming very soon, so let's see what the Chinese do. They've got to approve it. The deal is over to them right now." The White House did not immediately respond for comment when contacted by USA TODAY on Aug. 15. The next deadline for TikTok to be sold by ByteDance is Sept. 17. Some government officials are concerned that TikTok poses a national security threat, believing that ByteDance, which is based in Beijing, is sharing U.S. user data with China. TikTok has repeatedly denied these claims. In January, the platform went dark for less than 24 hours under federal legislation signed into law by former President Joe Biden in 2024. Trump has signed executive orders three times now that push back the deadline for when TikTok must be sold, promising that deals with China are on the horizon. The latest was in early July, when Trump told reporters aboard Air Force One that he was hopeful Chinese President Xi would agree to a deal to see the platform to the U.S.
Yahoo
28 minutes ago
- Yahoo
Amazon.com, Inc. (AMZN): Jim Cramer Maintains It Needs To Buy NVIDIA
We recently published . Inc. (NASDAQ:AMZN) is one of the stocks Jim Cramer recently discussed. Inc. (NASDAQ:AMZN) is struggling on the stock market lately as investors are worried about the growth prospects of its cloud computing division. The shares have gained a mere 1.4% over the past month, after they fell by 9.6% after the firm's second quarter earnings were accompanied by weak AWS growth. Cramer continues to maintain that Inc. (NASDAQ:AMZN) is struggling because it is focusing on its in-house AI chips instead of NVIDIA's AI GPUs: 'Think about what happened to Amazon, when they decided to go away from using all the NVIDIA that was possible. . . Copyright: veghsandor / 123RF Stock Photo Here are his previous thoughts about Inc. (NASDAQ:AMZN): 'We're in the era, this is what happens, The two big overhangs in this market had been Apple waiting for the sword of Damocles and Amazon, trading down because Amazon Web Services is viewed as a share donor. Both of those seem to have been forgotten. David, the forgotten negatives there has been replaced by we're dumping the big tariffs for now.' While we acknowledge the potential of AMZN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
28 minutes ago
- Yahoo
Aethlon Medical Inc (AEMD) Q1 2026 Earnings Call Highlights: Strategic Focus on Australian ...
Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aethlon Medical Inc (NASDAQ:AEMD) has made significant progress in its Australian oncology trial, with the first cohort of patients completing treatment without any device deficiencies or serious adverse events. The company has received formal approval from India's CDSCO to initiate an oncology trial, although they have decided to focus resources on the Australian trial for strategic reasons. Aethlon Medical Inc (NASDAQ:AEMD) has significantly reduced operating expenses by approximately 32%, primarily through payroll savings and reduced legal and consulting fees. The company is actively exploring the use of its hemo purifier for broader applications, including long COVID, and has presented promising pre-clinical data at a symposium. Aethlon Medical Inc (NASDAQ:AEMD) benefits from a 43% cash tax rebate in Australia, which helps offset research costs and makes conducting trials there financially advantageous. Negative Points The decision to not proceed with the Indian trial may delay potential strategic partnerships or regulatory approvals, as the company focuses solely on the Australian trial. Despite cost reductions, Aethlon Medical Inc (NASDAQ:AEMD) will still need to raise additional funds to continue its clinical research, as it does not yet have approved products for sale. The company faces challenges in accelerating patient enrollment in its Australian trial, although efforts are being made to address this through additional sites and recruitment strategies. The efficacy of the hemo purifier in actual clinical settings remains to be proven, as pre-clinical results may not directly translate to patient outcomes. Aethlon Medical Inc (NASDAQ:AEMD) is still in the early stages of its clinical trials, and it may take time to gather sufficient data to inform dosing and treatment effects. Q & A Highlights Warning! GuruFocus has detected 2 Warning Sign with AEMD. Q: Can you confirm if the primary endpoint of the Australian study is safety, and if the first cohort has shown no adverse events related to the hemo purifier treatment? A: Yes, the primary endpoint is safety. We have successfully passed the first cohort with no adverse events, and an independent data safety monitoring board has recommended moving forward to the second cohort. (Dr. Steven La Rosa, Chief Medical Officer) Q: The pre-clinical data showed a 98.5% removal of extracellular vesicles in a simulated treatment. Should we expect similar results in the clinical study with actual patients? A: Laboratory results often differ from clinical outcomes. The true test will be the reduction observed in actual patients, and we hope to have data from the first cohort soon. (Dr. Steven La Rosa, Chief Medical Officer) Q: With the decision not to proceed with the Indian trial, what does this mean for your cash needs and strategic focus? A: We will need to continue raising funds, ideally with strategic partners. The decision to halt the Indian trial was more about avoiding delays in approval processes rather than cost savings. (Jim Frakes, CEO and CFO) Q: Are there any advantages to conducting clinical research in Australia compared to India, especially regarding costs and incentives? A: Australia offers a significant tax rebate of about 43%, which is not available in India. This rebate can make conducting research in Australia more cost-effective despite lower hospital costs in India. (Jim Frakes, CEO and CFO) Q: What efforts are being made to accelerate patient enrollment in the Australian trial? A: We are actively working on several initiatives, including pre-screening logs, recruiting additional sites, and using clinical trial liaisons and social media campaigns to speed up enrollment. (Dr. Steven La Rosa, Chief Medical Officer) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
